As a world leader in pharmaceutical services, Almac delivers early formulation development work programs for DRF/PK/tox studies. Designed to maximize solubility and bioavailability without compromising on chemical stability, the studies accelerate drug development to the clinic and minimize risk in any downstream activities. Almac offer bespoke work packages specifically tailored to the physiochemical properties of the API (BCS class II, III, or IV) for solubility or permeability enhancement.

Read the full article below to find out more.